About Dr van Ginkel
Erik van Ginkel, M.D.
Board Certified in Family Practice
Addiction Medicine – Medical Management of Pain
PERSONAL
Erik van Ginkel, M.D.Miami, Florida 33143
Date of Birth: March 27, 1952
Place of Birth: Holland
OFFICE
Erik van Ginkel, M.D.
7000 sw 62 av suite 400
Tel; 305 665 0585
e-mail: md@miamipainandrecovery.com
Website:miamipainandrecovery.com
South Miami Clinical Research, LLC
7000 S.W. 62nd Avenue, Suite 402
South Miami, Florida 33143
EMPLOYMENT
1988 – 2000 Private Practice in Family Medicine, Miami, Florida
1991– 1993 Assistant Director , South Miami Hospital
Addiction Treatment Program
1992– 2007 Director, South Miami Hospital
Addiction Treatment Program
2008 – Present Private Practice in Family Medicine
Pain Management and Addictive Disease
EDUCATION
1985– 1988 Residency in Family Practice, University of Texas – Houston, Texas
1983 - 1985 Fellowship in Surgical Nutrition- Saint Luke’s Episcopal Hospital
Houston, Texas
1981 – 1983 Fellowship in General Surgical – Amsterdam, The Netherlands
1973 – 1981 Medical School, Free University of Amsterdam-Amsterdam,
The Netherlands
PROFESSIONAL MEMBERSHIP
AMA, American Society of Addiction Medicine, American Pain Society
CERTIFICATIONS/LICENSES
Licensed MRO 2009
Board Certified in Family Practice 1988 – 2012
Medical Licensure in the State of Florida 1988 – 2009
American Society of Addiction Medicine 1995
Educational Council for Foreign Medicine Graduates
Licensed to Practice Medicine in the Netherlands 1981
LANGUAGES
English, Dutch, French, and German – Fluent
Spanish - basic
CLINICAL RESEARCH EXPERIENCE
2006-2007 Phase III, HIV
2006-2006 Phase III, Mild Hypertension
2006-2006 Phase III, Hyperlipdemia
2005-2006 Phase II, Hypercholesterolemia
2005-2005 Phase IIIB, Gout
2005-2005 Phase III, Mild to Moderate Asthma
2005-2005 Phase III, COPD
Avexa Ltd-Protocol No. AVX-301 Phase 2b/3 HIV-1 Infected Patients
February 2008 – 2009
Novartis Pharmaceuticals-Protocol No. CQAB149B2335S / Extension Phase II/III COPD
August 2007 – April 2009
Novartis Pharmaceuticals-Protocol No. CNVA237A2206 Phase II COPD
September 2007 - February 2008
Tap Pharmaceuitcals Products, Inc.-Protocol No. F-GT06-153 Phase III Gout
March 2007 - May 2008
Novartis Pharmaceuticals-Protocol No. CQAB149B2338 Phase III Asthma
March 2008 - October 2008
Novartis Pharmaceuticals-Protocol No. CQAB149B2346 Phase III COPD
February 2008 - September 2008
GlaxoSmithKline-Protocol N0. ADC111891 Phase IV COPD
November 2008 – June 2009
Novartis Pharmaceuticals-Protocol No. CQAB149B2349 Phase IIIB COPD
February 2009 - Present
Novartis Pharmaceuticals-Protocol No. CIGE025AUS33 Phase IV Asthma
February 2009 - Present
CLINICAL RESEARCH EXPERIENCE
Novartis Pharmaceuticals-Protocol No. CSPV100AU01 Phase IV Hypertension
February 2009 - Present
GlaxoSmithKline-Protocol N0. PXN110527 Phase IIa Neuropathic Pain
February 2009 – Present
Speakers bureau
Purdue
Pfizer
Reckitt Benckiser
Endo
King
CO-HOST ON RADIO PROGRAM; reality radio
880 AM “the biz” wednesday NIGHTS FROM 9-11 PM
